Cargando…

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yu-Chien, Wen, Kuo-Chang, Sung, Pi-Lin, Chou, Yu-Ting, Liew, Phui-Ly, Chen, Lin-Yu, Huang, Rui-Lan, Lai, Hung-Cheng, Chang, Lu-Te
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725117/
https://www.ncbi.nlm.nih.gov/pubmed/33292376
http://dx.doi.org/10.1186/s13048-020-00751-3
_version_ 1783620646773719040
author Lin, Yu-Chien
Wen, Kuo-Chang
Sung, Pi-Lin
Chou, Yu-Ting
Liew, Phui-Ly
Chen, Lin-Yu
Huang, Rui-Lan
Lai, Hung-Cheng
Chang, Lu-Te
author_facet Lin, Yu-Chien
Wen, Kuo-Chang
Sung, Pi-Lin
Chou, Yu-Ting
Liew, Phui-Ly
Chen, Lin-Yu
Huang, Rui-Lan
Lai, Hung-Cheng
Chang, Lu-Te
author_sort Lin, Yu-Chien
collection PubMed
description BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy failed. Cachexia was induced by the disseminating recurrent tumors. Tumor tissue staining and genomic analysis revealed PD-L1 negativity, a low tumor burden, stable microsatellite instability, and two mutations in ARID1A. The patient was administered pembrolizumab combined with bevacizumab triweekly. Her serum CA-125 level decreased dramatically after the first cycle. A computerized tomography scan showed marked regression of the recurrent masses after 3 cycles, and the patient reached complete remission after 9 cycles. She showed good recovery from cachexia. We observed no marked side effects except for mild polyarthritis of the small joints. CONCLUSIONS: The therapeutic effect of checkpoint inhibitors combined with angiogenesis inhibitors is very promising in our patient with OCCC. Further clinical trials of tumors including ARID1A mutations are warranted.
format Online
Article
Text
id pubmed-7725117
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77251172020-12-10 Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report Lin, Yu-Chien Wen, Kuo-Chang Sung, Pi-Lin Chou, Yu-Ting Liew, Phui-Ly Chen, Lin-Yu Huang, Rui-Lan Lai, Hung-Cheng Chang, Lu-Te J Ovarian Res Case Report BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy failed. Cachexia was induced by the disseminating recurrent tumors. Tumor tissue staining and genomic analysis revealed PD-L1 negativity, a low tumor burden, stable microsatellite instability, and two mutations in ARID1A. The patient was administered pembrolizumab combined with bevacizumab triweekly. Her serum CA-125 level decreased dramatically after the first cycle. A computerized tomography scan showed marked regression of the recurrent masses after 3 cycles, and the patient reached complete remission after 9 cycles. She showed good recovery from cachexia. We observed no marked side effects except for mild polyarthritis of the small joints. CONCLUSIONS: The therapeutic effect of checkpoint inhibitors combined with angiogenesis inhibitors is very promising in our patient with OCCC. Further clinical trials of tumors including ARID1A mutations are warranted. BioMed Central 2020-12-08 /pmc/articles/PMC7725117/ /pubmed/33292376 http://dx.doi.org/10.1186/s13048-020-00751-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Lin, Yu-Chien
Wen, Kuo-Chang
Sung, Pi-Lin
Chou, Yu-Ting
Liew, Phui-Ly
Chen, Lin-Yu
Huang, Rui-Lan
Lai, Hung-Cheng
Chang, Lu-Te
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
title Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
title_full Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
title_fullStr Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
title_full_unstemmed Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
title_short Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
title_sort complete remission of heavily treated ovarian clear cell carcinoma with arid1a mutations after pembrolizumab and bevacizumab combination therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725117/
https://www.ncbi.nlm.nih.gov/pubmed/33292376
http://dx.doi.org/10.1186/s13048-020-00751-3
work_keys_str_mv AT linyuchien completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT wenkuochang completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT sungpilin completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT chouyuting completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT liewphuily completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT chenlinyu completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT huangruilan completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT laihungcheng completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport
AT changlute completeremissionofheavilytreatedovarianclearcellcarcinomawitharid1amutationsafterpembrolizumabandbevacizumabcombinationtherapyacasereport